The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and…

1,723 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease (2013, neutral): “On the other hand NASH may be present in up to 3% of the general population and in up to two thirds of individuals with morbid obesity and/or type 2 diabetes [4,8].”
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. (2017, background): “REFERENCES [1] Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al.”
The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota (2016, background): “As previously described,((27)) the presence of the MetS was strongly associated with more severe NAFLD lesions (Fig.”
Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss (2022, background): “NAFLD patients may present with elevated liver enzymes [6].”
Role of Dietary Fructose and Hepatic de novo Lipogenesis in Fatty Liver Disease (2016, background): “Nonalcoholic fatty liver disease is defined as excessive hepatic lipid accumulation in individuals who have no apparent liver disease and whose alcohol intake is less than 30 g per day for men and 20 g per day for women (*10 g of alcohol per one drink unit) [7].”